Bazlitoran clinical trials
Also written IMO-8400.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2013
How each study uses bazlitoran is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- IMO-8400
- 2
Studies by the year they started
5 studies that test it; most in 2014 (3)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Idera Pharmaceuticals, Inc. (5)
Studies
Open first, then newest update. How each study uses bazlitoran is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A 12-week Dose-Ranging Trial in Patients With Moderate to Severe Plaque PsoriasisCompletedPhase 2Idera Pharmaceuticals, Inc.NCT01899729Written as IMO-8400 Regimen 1
- Trial of IMO-8400 in Adult Patients With DermatomyositisCompletedPhase 2Idera Pharmaceuticals, Inc.NCT02612857Written as IMO-8400 Dose Group 1
- Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's MacroglobulinemiaTerminatedPhase 1/2Idera Pharmaceuticals, Inc.NCT02092909Written as IMO-8400
- Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401CompletedPhase 1/2Idera Pharmaceuticals, Inc.NCT02363439Written as IMO-8400 0.6 mg/kg/wk or 1.2 mg/kg twice weekly
- Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P MutationCompletedPhase 1/2Idera Pharmaceuticals, Inc.NCT02252146Written as IMO-8400
Codes
What other systems call bazlitoran · ClinicalTrials.gg INT001708
- MeSH (NLM) C000719091bazlitoranOne source NLM
- UNII (FDA) 2U46M95B5MBAZLITORANConfirmed FDA, NLM
- NCI Thesaurus C114975BazlitoranOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000719091 | bazlitoran | One source NLM |
| UNII (FDA) | 2U46M95B5M | BAZLITORAN | Confirmed FDA, NLM |
| NCI Thesaurus | C114975 | Bazlitoran | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.